ArticleChina CDC weekly2026
Epidemiological Characteristics and Spatiotemporal Cluster Analysis of Multidrug-Resistant and Rifampicin-Resistant Tuberculosis Among Older People - China, 2019-2025.
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Drug Resistance Patterns, Temporal Trends, and Risk Factors Among Elderly Tuberculosis Patients in Anhui, China: A Retrospective Study (2020-2024).Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) in older individuals remains a significant public health challenge in China. This study evaluated the epidemiological characteristics and spatiotemporal patterns of MDR/RR-TB in individuals aged ≥65 years in China between 2019 and 2025. Methods: Data were obtained from the China Information System for Disease Control and Prevention (CISDCP). Spatiotemporal distribution and demographic characteristics of MDR/RR-TB cases in China were analyzed using descriptive epidemiological methods. Global Moran's Results: From 2019 to 2025, 21,569 patients with MDR/RR-TB aged ≥65 years were registered across 31 provincial-level administrative divisions nationwide [1.72% of all pulmonary tuberculosis (PTB) in older patients]. The notification rate of MDR/RR TB among older people declined in 2022 and then rebounded in 2025. The proportion of MDR/RR-TB among older patients with PTB increased. The patients were predominantly male (73.3%) in the 65-69-year age group. Of the cases, 46.0% were retreated, and 83.3% underwent molecular diagnostic testing. Heilongjiang and Gansu were persistent high-high cluster areas, whereas Xinjiang presented the highest risk. Spatiotemporal scanning identified significant clusters in Xinjiang, the three northeastern provinces, Chongqing-Guizhou, and Ningxia-Shaanxi-Gansu. Conclusions: The proportion of MDR/RR-TB among older patients with PTB in China increased significantly. The clusters were mainly located in the central-western and northeastern regions. We recommend strengthening drug resistance surveillance, expanding molecular testing coverage in high-risk areas, and optimizing treatment strategies for retreated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.